Kantonsspital Graubunden

Futó vizsgálatok

• Toboroz

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· 3. fázis· Forrás

• Toboroz

  Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)

  NCT07365423· 2. fázis· Forrás

• Toboroz

  A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  NCT07293351· 1/2. fázis· Forrás

• Toboroz

  A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07023627· 2. fázis· Forrás

• Toboroz

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· 3. fázis· Forrás

• Toboroz

  Fiber-Boost Randomized Controlled Trial

  NCT07483112· Forrás

• Toboroz

  Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

  NCT07106762· 2/3. fázis· Forrás

• Toboroz

  Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer

  NCT07617610· Forrás

• Toboroz

  Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

  NCT06697301· 2/3. fázis· Forrás

• Fut, nem toboroz

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· 3. fázis· Forrás

• Toboroz

  Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

  NCT06358573· 2. fázis· Forrás

• Fut, nem toboroz

  Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

  NCT05688280· 1/2. fázis· Forrás

• Fut, nem toboroz

  A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT05160584· Forrás

• Fut, nem toboroz

  Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

  NCT04604067· 2. fázis· Forrás

• Fut, nem toboroz

  Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

  NCT04608318· 3. fázis· Forrás

• Fut, nem toboroz

  Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

  NCT04595565· 3. fázis· Forrás

• Toboroz

  A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  NCT04389632· 1. fázis· Forrás

• Toboroz

  Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

  NCT05017142· Forrás

• Toboroz

  Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care

  NCT04300257· Forrás

• Toboroz

  The SwissPrEPared Study

  NCT03893188· Forrás

• Fut, nem toboroz

  Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

  NCT03540420· 2. fázis· Forrás

• Toboroz

  International Registry for Men With Advanced Prostate Cancer (IRONMAN)

  NCT03151629· Forrás

• Toboroz

  Swiss Primary Biliary Cholangitis Cohort Study

  NCT03146910· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Petefészekrák3 toboroz
• Gyermekkori daganatok2 toboroz
• Hólyagrák2 toboroz
• Tüdőrák2 toboroz
• Fej-nyaki daganatok1 toboroz
• Gyomor- és nyelőcsőrák1 toboroz
• Hasnyálmirigyrák1 toboroz
• HIV-fertőzés1 toboroz
• Méhnyakrák1 toboroz
• Melanóma1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Neuromyelitis optica (NMOSD)1 toboroz
• Primer biliáris cholangitis (PBC)1 toboroz
• Prosztatarák1 toboroz
• Sclerosis multiplex (SM)1 toboroz
• Szarkóma1 toboroz
• Tripla negatív emlőrák1 toboroz
• Vastagbélrák1 toboroz
• Vesedaganat1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Toboroz

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· 3. fázis· Forrás

• Visszavonták

  AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC

  NCT06068153· 2. fázis· Forrás

• Lezárult

  Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome

  NCT05497089· 2. fázis· Forrás

• Lezárult

  Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.

  NCT03993678· 1/2. fázis· Forrás

• Lezárult

  BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

  NCT03762018· 3. fázis· Forrás

• Leállították

  Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

  NCT03708003· 2. fázis· Forrás

• Lezárult

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· 3. fázis· Forrás

• Lezárult

  Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

  NCT03297593· 2. fázis· Forrás

• Lezárult

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· 3. fázis· Forrás

• Leállították

  Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

  NCT02051218· 3. fázis· Forrás